Eva Wesley

French biotech supplier Verdot has opened a €10 million production facility in Auvergne, increasing manufacturing capacity by approximately 150%. The company produces purification equipment for biopharmaceutical manufacturers, including major pharmaceutical and biotechnology companies. The investment aims to support international growth, particularly in North America and Asia, while strengthening Verdot's industrial presence in France.

AstraZeneca will invest $2 billion in biotech company Summit Therapeutics to support cancer research. The partnership focuses on ivonescimab, an experimental treatment targeting two cancer-related pathways. The companies plan new clinical trials combining ivonescimab with other therapies. The agreement strengthens collaboration between the companies and provides Summit with significant funding for development.

Biofábrica Misiones has restarted production of medicinal cannabis oil after a year-long interruption, reopening a supply line intended for patients in Argentina's Misiones province who hold medical prescriptions. The biotechnology company said it expects to provide the public health system with at least 1,000 bottles each month, with deliveries beginning September 25 at no cost.

Argentine biotech startup CycleF is expanding the use of nanotechnology in agriculture with a bioestimulant designed to help crops withstand drought, frost and other stresses. Founded by three scientists with more than US$100,000 in initial capital, the company already treats 10,000 hectares and expects 2026 revenue above US$900,000, while developing additional circular solutions for farmers.

Chilean biotech company BioUp has expanded its veterinary research business internationally, serving clients in six countries across the Americas. Founded in 2020 at Universidad Mayor, the company conducts clinical trials, develops diagnostic and therapeutic technologies, researches vaccines and provides regulatory support. Its model turns specialized veterinary science and biotechnology into an exportable service.

Infood Protein, a biotech startup from Valdivia, Chile, will pilot its agricultural biostimulant Hermia in Colombia with flower exporter Prime Flowers on hydrangea crops. The agreement emerged from the GoGlobal 2026 mission with ProChile, which ran in Medellín and Bogotá. If results are positive, Prime Flowers could adopt the product permanently. Terms were not disclosed.

Maximiliano Venegas, a researcher at Chilean fungi biotechnology startup Spora, said the company is beginning to sell a mycelium-based textile to premium buyers in Europe through advisers in the United Kingdom. The interview, published on 8 October 2026, also covers an early-stage Corfo-funded psilocybin project for chronic pain and his warning about unstandardized mushroom supplements.

Argentine biotech CrofaBiotech, which is developing genetically modified pigs for human organ transplants, has raised $6.7 million, Forbes Argentina reported on October 14th 2026. The reported total combines a $700,000 pre-seed and a $6 million seed round. Funds will help build specialized pig facilities, with advanced trials expected in about two years, subject to approvals.

AMC Bio has acquired the CYCLOPE project from French technology-transfer partners to advance a potential antiviral treatment targeting dengue, Zika, chikungunya and West Nile virus. Developed through collaboration between chemists and virologists, the programme aims to target a host-cell mechanism shared by several viruses. Preclinical development remains necessary before clinical efficacy can be established.

Flavii Therapeutics, a spin-off of the University of Barcelona, has raised €843,000 in a funding round led by Grow Venture Partners, with participation from ICF, WA4STEAM and private investors. The funding will support preclinical and regulatory studies of FLAV-27, an epigenetics-based candidate showing promising results in experimental models of Alzheimer's, Huntington's disease and autism.